Long-term outcomes after induction chemotherapy with docetaxel, cisplatin and 5-FU (TPF) followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal cancer.

被引：0
|
作者：
Cho, Sang-Hee
Shim, Hyun-Jeong
Hwang, Jun-Eul
Bae, Woo Kyun
Chung, Ik-Joo
机构：
[1] Chonnam Natl Univ, Hwasun Hosp, Dept Hemato Oncol, Hwasun, South Korea
[2] Chonnam Natl Univ, Hwasun Hosp, Hwasun, South Korea
[3] Chonnam Natl Univ, Hwasun Hosp, Dept Med Oncol, Hwasun, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e18008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18008
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II study of docetaxel, cisplatin and 5-FU induction chemotherapy followed by concurrent chemoradiotherapy for advanced nasopharyngeal cancer
    Cho, S.
    Bae, W.
    Hwang, J.
    Shim, H.
    Lee, J.
    Lim, S.
    Chung, W.
    Chung, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Long-term complication and outcomes after induction chemotherapy with TPF followed by chemoradiotherapy for nasopharyngeal cancer
    Cho, S-H.
    Chung, I. J.
    Bae, W. K.
    Hwang, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer
    Bae, Woo Kyun
    Hwang, Jun Eul
    Shim, Hyun Jeong
    Cho, Sang Hee
    Lee, Joon Kyoo
    Lim, Sang-Chul
    Chung, Woong-Ki
    Chung, Ik-Joo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (03) : 589 - 595
  • [4] Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer
    Woo Kyun Bae
    Jun Eul Hwang
    Hyun Jeong Shim
    Sang Hee Cho
    Joon Kyoo Lee
    Sang-Chul Lim
    Woong-Ki Chung
    Ik-Joo Chung
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 589 - 595
  • [5] Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin in locally advanced stage III and IV nasopharyngeal cancer.
    Dane, Faysal
    Atasoy, Beste Melek
    Akgun, Zuleyha
    Yumuk, Fulden
    Cabuk, Devrim
    Teomete, Mehmet
    Basaran, Gul
    Turhal, Serdar
    Abacioglu, Ufuk
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Prognostic markers for oropharyngeal cancer after docetaxel, 5-FU, and cisplatin induction chemotherapy followed by concurrent chemoradiotherapy.
    Cho, Sang-Hee
    Bae, Woo Kyun
    Shim, Hyun-Jeong
    Choi, Won-Young
    Hwang, Jun-Eul
    Choi, Yoo-Duk
    Lim, Sang-Chul
    Chung, Ik-Joo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] TPF induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: Long term results of a Tunisian series
    Toumi, N.
    Ben Kridis, W.
    Mnejja, W.
    Bouzguenda, R.
    Khanfir, A.
    Ghorbel, A.
    Daoud, J.
    Frikha, M.
    CANCER RADIOTHERAPIE, 2018, 22 (03): : 216 - 221
  • [8] A Phase II study of docetaxel, cisplatin, and 5 FU induction chemotherapy followed by chemoradiotherapy in advanced nasopharyngeal cancer
    Bae, W.
    Cho, S.
    Hwang, J.
    Shim, H.
    Lee, J.
    Lim, S.
    Chung, W.
    Chung, I.
    EJC SUPPLEMENTS, 2009, 7 (02): : 488 - 489
  • [9] Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma
    Takamizawa, Shigemasa
    Honma, Yoshitaka
    Murakami, Naoya
    Mori, Taisuke
    Oka, Hiroki
    Yamamoto, Shun
    Kashihara, Tairo
    Ito, Kimiteru
    Kubo, Yuko
    Ikeda, Atsuo
    Matsumoto, Fumihiko
    Omura, Go
    Kobayashi, Kenya
    Itami, Jun
    Kato, Ken
    Yoshimoto, Seiichi
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (02) : 564 - 570
  • [10] Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma
    Shigemasa Takamizawa
    Yoshitaka Honma
    Naoya Murakami
    Taisuke Mori
    Hiroki Oka
    Shun Yamamoto
    Tairo Kashihara
    Kimiteru Ito
    Yuko Kubo
    Atsuo Ikeda
    Fumihiko Matsumoto
    Go Omura
    Kenya Kobayashi
    Jun Itami
    Ken Kato
    Seiichi Yoshimoto
    Investigational New Drugs, 2021, 39 : 564 - 570
12345